Injectability is a common screening criteria when determining the candidacy of protein therapeutics. Often times, the candidate protein therapeutics are scrutinized if the viscosity is higher than the pre-set threshold where the cut off viscosity ranges from 20 to 40 mPa-s depending on the delivery device. However, this type of generalization without specifying the shear rate could potentially lead to a false negative determination of an otherwise excellent therapeutic resulting in significant financial loss and time during development.
To avoid this pitfall, the best practice is to estimate injectability with the viscosity at the shear rate inside the needle during injection and not the visocsity measured at an arbitrary low shear rate (often 1,000 1/s).
Download our new application note where we help provide details on avoiding such potential pitfalls: